Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Denali Therapeutics (DNLI) Net Margin: 2018-2023

Historic Net Margin for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2023 value amounting to -7,841.59%.

  • Denali Therapeutics' Net Margin fell 493912.00% to -7,841.59% in Q3 2023 from the same period last year, while for Sep 2023 it was -122.53%, marking a year-over-year increase of 15777.00%. This contributed to the annual value of -43.94% for FY2023, which is 25662.00% up from last year.
  • Denali Therapeutics' Net Margin amounted to -7,841.59% in Q3 2023, which was down 20,909.04% from -37.32% recorded in Q2 2023.
  • Over the past 5 years, Denali Therapeutics' Net Margin peaked at 77.30% during Q4 2020, and registered a low of -7,841.59% during Q3 2023.
  • In the last 3 years, Denali Therapeutics' Net Margin had a median value of -601.41% in 2021 and averaged -1,438.73%.
  • Its Net Margin has fluctuated over the past 5 years, first skyrocketed by 308,957bps in 2019, then tumbled by 493,912bps in 2023.
  • Quarterly analysis of 5 years shows Denali Therapeutics' Net Margin stood at -1,156.36% in 2019, then spiked by 123,365bps to 77.30% in 2020, then plummeted by 67,871bps to -601.41% in 2021, then slumped by 35,821bps to -959.62% in 2022, then tumbled by 493,912bps to -7,841.59% in 2023.
  • Its last three reported values are -7,841.59% in Q3 2023, -37.32% for Q2 2023, and -312.40% during Q1 2023.